The project will focus on delivering prescriptions only where there is clear evidence they will be effective.
Researchers will improve diagnostic techniques and guide health care professionals in the treatment of infectious diseases.
In some settings, antibiotics – which are effective on bacterial, but not viral infections – are unnecessarily prescribed. This can accelerate the emergence of bacterial strains that are resistant to antibiotics.
Researchers will encourage wider use of tests to find out what type of infection a patient has.
VALUE-Dx aims to gather evidence on the medical, economic, and public health benefits of improved diagnostics in tackling AMR.
Edinburgh is joined in partnership by University Hospital Antwerp, University Medical Center Utrecht, Universitair Medisch Centrum Groningen, Universidad De La Rioja, University of Oxford, University of Verona and the University of Antwerp.
VALUE-Dx has been launched by the Innovative Medicines Initiative (IMI) – a partnership between the European Union and the European pharmaceutical industry.
The four-year initiative is co-funded by the European Commission (IMI), the Wellcome Trust and private partners.
This is an exciting opportunity to focus on the value rapid diagnostics provide in the fight against AMR. This will further enhance Edinburgh's leading position in AMR diagnostics.
Dr Till Bachmann, Division of Infection of Pathway Medicine, University of Edinburgh
Source: University of Edinburgh